Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ad scientiam
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 to 70 Years
Diagnostic and Statistical Manual of Mental Disorders-5 criteria for MDD
Score \> 21 on HDRS-17
Initiation of an antidepressant treatment for the current episode (first line or second line treatment, ...)
Ability to use a mobile application
Agreement to use the study mobile if he/she does not own an iPhone 5 or newer
Enrolled in or benefiting of a Social Security program
Having read the information sheet and signed the informed consent form
Serious suicidal risk, identified by the Mini International Neuropsychiatric Interview (MINI)
Perinatal depression
Seasonal affective disorder
Psychiatric comorbidities: bipolar disorder, obsessive-compulsive disorder, post-traumatic stress, psychotic disorder, anorexia nervosa, bulimia nervosa, personality disorder identified by the MINI questionnaire
Alcohol addiction or abuse, identified by the MINI questionnaire
Substance related disorders non-alcoholic addiction or abuse (opioids, cocaine, cannabis, sedatives, stimulants, hallucinogens, inhalants, solvents), identified by the MINI questionnaire
Under neurostimulation (\< 6 months before inclusion day)
Patient under Temporary Use Authorisation (TUA)
Patients with Monoamine Oxidase Inhibitor (MAOIs), tricyclic antidepressant
Patient with electroconvulsive therapy (ECT) history for current episode
Patient with a somatic pathology
Scheduled hospitalization for more than 7 days
Antecedent of major head trauma
Seizures
Systemic medical diseases that are likely to affect cognitive functioning
Pregnant and nursing women
Wearers of pacemakers, implantable defibrillators
Subjects not proficient in French
Person under guardianship or curators
Illiterate subjects
Participation to another interventional clinical trial (category 1)
You may not be if
Serious suicidal risk, according to clinician's judgement
Discontinuation or change of AD treatment before 4 weeks after the dose initiation in the phase 1 and 2
Initiation of a structured psychotherapy or neurostimulation
Initiation of treatment with MAOIS
Introduction of benzodiazepines at regular doses. Limited use (≤7 consecutive days or several periods of ≤3 consecutive days) is authorized
Alcohol and substances abuse related disorders (opioids, cocaine, cannabis, sedatives, stimulants, hallucinogens, inhalants, solvents), according to clinician's judgement.
Patient under Temporary Use Authorisation (TUA)
Clareo Health | Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale
